The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 6 of the 21 sources its claims cite were checked for support.
Abstract
INTRODUCTION: Previous societal burden estimations for major depressive disorder (MDD) often fail to account for several hidden cost components. This study provides a comprehensive evaluation of societal costs for adults with MDD in the United States (USA) in 2019. The potential impact of a more effective, rapid-acting MDD therapy vs standard of care on the economic burden of MDD was estimated to illustrate the utility of such a framework in evaluating new interventions. METHODS: This study used a prevalence-based human capital approach. Incremental costs (2019 US dollars) per individual with MDD were derived from national survey inputs and published literature and included incremental healthcare costs and indirect costs. For each cost component, the societal costs were extrapolated by multiplying the per-patient costs by the number of individuals with MDD. The impact of a more effective, rapid-acting novel therapy on the economic burden of MDD was then simulated on the basis of these inputs. RESULTS: In 2019, the number of adults with MDD in the USA was estimated at 19.8 million (62.7% female; 32.9% severe MDD), and the incremental societal economic burden of MDD was estimated at $333.7 billion ($382.4 billion in 2023 US dollars), or $16,854 per adult with MDD. The primary cost drivers were healthcare costs ($127.3 billion; 38.1%), household-related costs ($80.1 billion; 24.0%), presenteeism ($43.3 billion; 13.0%), and absenteeism ($38.4 billion; 11.5%). In the simulated scenario, a hypothetical novel therapy with a 50.0% early response rate was associated with a 7.7% reduction in the economic burden of MDD relative to standard of care over 12 months. CONCLUSIONS: The economic burden of MDD is substantial and extends beyond healthcare costs, underscoring the impact of MDD across multiple aspects of life. Such a broad societal perspective should be considered in assessing the impact of the advent of effective, rapid-acting MDD therapies.
Overview
CoChat Summary
TL;DR
This study estimates the 2019 societal economic burden of major depressive disorder (MDD) among US adults at $333.7 billion, or $16,854 per adult with MDD, with most costs driven by indirect components. A hypothetical simulation suggests a more effective, rapid-acting therapy could reduce the incremental economic burden by 7.7%.
Key findings
- The total incremental economic burden of MDD in US adults in 2019 was $333.7 billion ($382.4 billion in 2023 USD), or $16,854 per adult with MDD; indirect costs accounted for 61.9% ($206.4 billion) of the total.
- Household-related costs were $80.1 billion (24.0% of total burden), representing 38.8% of all indirect costs and borne by adults without MDD living with an adult with MDD.
- MDD prevalence among US adults was 7.8%, equivalent to 19.8 million adults; 67.1% had moderate and 32.9% had severe symptoms, and 62.7% of the MDD population were female.
- In a simulation assuming a novel therapy with early response of 50.0% versus 19.8% for standard care, the incremental economic burden fell to $308.0 billion, a 7.7% reduction; sensitivity analyses ranged from $254.4 billion to $418.6 billion.
Methods
- Prevalence-based human capital approach using a bottom-up method: average per-patient incremental costs were multiplied by the estimated number of US adults with MDD.
- Cost components included healthcare costs, unemployment, absenteeism, presenteeism, disability, all-cause mortality, and household-related costs, stratified by gender and MDD severity where available.
- Inputs came from national survey data (NSDUH, NHANES), US Census Bureau data, claims-based studies, and published literature; a hypothetical simulation assessed the impact of a rapid-acting novel MDD therapy.
Limitations
- The paper states that cost estimates should be interpreted as associations rather than causation, and that reliance on multiple literature-based estimates may under- or overestimate certain cost components.
- The paper states that MDD prevalence used NSDUH major depressive episode data as a proxy, with possible self-report bias, and that individuals with mild depressive symptoms (PHQ-9 score <10) were assumed not to qualify for MDD, potentially missing some burden.
- The paper states that the novel therapy simulation was hypothetical, assumed all treated patients would switch to the novel therapy, and did not account for long-term life-course effects; the text also makes evident that the study was funded by Biogen Inc. and Sage Therapeutics, Inc., with several authors employed by or consulting for industry.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
3 Valid · 3 Not valid · 13 Not checked · 62 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The current estimate of total incremental costs of MDD in 2019 represents a 3.5% increase in the burden compared with a prior estimate in 2018 (when standardized to 2019 values), with 36.0% of the total incremental costs of MDD in 2019 coming from novel components not previously included in the prior estimate (i.e., unemployment, all-cause mortality, householdrelated costs) [8].”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > DISCUSSION
What the sources say
- Disputedcites [8] Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021;39(6):653–65. sourceExperimental — accuracy not yet measured
Our copy of Greenberg et al. (2021) reports only a 2010-vs-2018 comparison in year 2020 values: the incremental burden rose from $US236.6B to $US326.2B, an increase of 37.9% (§3.2 MDD Costs: 2010 vs. 2018; Abstract), with the 2018 composition being 35% direct, 4% suicide-related and 61% workplace costs — no 2019 estimate and no 3.5% figure appear anywhere. The claim's 'novel components' are also contrary to what the paper says: §4.2 Limitations states that 'potentially important cost categories were not incorporated into the methodology, thereby resulting in understated estimates' (student/career effects, caregiver burden, quality-of-life), and its only mortality component is suicide-related cost with 50% of suicides attributed to MDD (§2.4), not all-cause mortality, unemployment or household-related costs. Searches for '2019 values / 3.5%', 'unemployment, all-cause mortality, household-related costs' returned nothing supporting the attributed numbers. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“one of the key differentiators of the current study from previous estimations of the economic burden of MDD [8,33,34] was the consideration of household-related costs.”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > DISCUSSION
What the sources say
- Supportedcites [8] Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021;39(6):653–65. source
The citation identifies this paper as a previous estimate of MDD’s economic burden, rather than attributing the citing study’s household-cost analysis to it. The Introduction describes an update of earlier estimates focused on direct, suicide-related, and workplace costs; the Limitations section notes that caregiver burdens were not incorporated. This supports the stated distinction. (LLM, conf=0.91)
- Not checked yetcites [33] Chow W, Doane MJ, Sheehan J, et al. Clinical brief. Economic burden among patients with major depressive disorder: an analysis of healthcare resource use, work productivity, and direct and indirect costs by depression severity. Am J Manag Care. 2019. (Supplements and Featured Publications. February 2019). https://www.ajmc.com/view/economic-burden-mdd.
- Partly supportedcites [34] Jain S, Gupta S, Li VW, et al. Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis. BMC Psychiatry. 2022;22(1):542. sourceExperimental — accuracy not yet measured
The Background identifies this as a study of depression’s economic burden, and Methods > Measures describes its work-productivity and healthcare-utilization measures. It therefore supports citing the paper as earlier economic-burden research, but our copy does not report a monetary cost estimate. The statement about household-related costs is the citing authors’ description of their own study, not a finding attributed to this source. (LLM, conf=0.79)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given that MDD is highly comorbid with other mental and physical health conditions [7,43]”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > DISCUSSION
What the sources say
- Partly supportedcites [7] Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75(4):336–46. sourceExperimental — accuracy not yet measured
The Discussion and Table 2 report substantial comorbidity between MDD and other psychiatric disorders, including anxiety and substance use disorders. The passages do not establish comorbidity with physical health conditions; the physical conditions found in the References are titles of other works. Page numbers are not available in our copy. (LLM, conf=0.85)
- Not checked yetcites [43] Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003;160(12):2122–7. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The total incremental economic burden of adults with MDD in the USA in 2019 was estimated at $333.7 billion (equivalent to $382.4 billion in 2023 USD), or $16,854 per adult with MDD (Table 1); women with MDD accounted for 52.6% of the total burden.”
- Also stated in: § DISCUSSION · plain
“The total incremental costs associated with MDD in 2019 amounted to $333.7 billion (equivalent to $382.4 billion in 2023 USD), or $16,854 per adult with MDD, which was driven by indirect costs (61.9%),”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > Economic Burden of MDD
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The total incremental economic burden of adults with MDD in the USA in 2019 was estimated at $333.7 billion (equivalent to $382.4 billion in 2023 USD), or $16,854 per adult with MDD (Table 1); women with MDD accounted for 52.6% of the total burden.”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > Economic Burden of MDD
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims
Create a free account to see all 81 claims and to verify the 15 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 17
- The quote only partly states this claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This finding suggested that the immense economic burden caused by depressive disorder may have deteriorated in recent decades, which aligns with the findings from a 2019 study [19].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > CONCLUSIONS
“| Disability | $4,621,054,657 | $2,834,898,257 | $1,786,156,400 |”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > DISCUSSION
“Employed male with MDD 4,686,307 $242 $1,764,389,407 [12]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > DISCUSSION
“A third of the total count of suicides in the USA in 2019 (30,899 out of 45,861 suicides) were attributed to MDD”
§ The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) > Mortality
“In 2019, there were an estimated 30,899 incremental deaths among adults with MDD in the USA, of which 15,272 were estimated to be due to suicide, accounting for one-third of all suicides that year.”
Citations
Cites
Mental health and the COVID-19 pandemic
Pfefferbaum, B., & North, C. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2008017 · Cited by 4,378 · cited 17×
“A third of the total count of suicides in the USA in 2019 (30,899 out of 45,861 suicides) were attributed to MDD, which accounted for 50% of the excess all-cause deaths among adults with MDD in 2019.”
BackgroundInfluentialPrevalence of and Risk Factors for Lifetime Suicide Attempts in the National Comorbidity Survey
Kessler, R. C., Borges, G., & Walters, E. E. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.7.617 · Cited by 2,514
Self-citationPrevalence of depression symptoms in US adults before and during the COVID-19 pandemic
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19686 · Cited by 2,138
“Pandemic fear” and COVID-19: mental health burden and strategies
Ornell, F., Schuch, J. B., Sordi, A. O., & Kessler, F. H. P. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0008 · Cited by 1,852 · cited 1×
“The pandemic has brought fundamental changes to the lifestyle, work routine, and social relationships of the US population, and there could be long-lasting effects even after the pandemic subsides [47].”
BackgroundEpidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Given that MDD is highly comorbid with other mental and physical health conditions [7, 43], which may exert reciprocal impacts on disease severity and management, the burden of MDD is likely partially embodied in the economic assessments of other mental and physical health conditions.”
BackgroundMokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
Cost of Lost Productive Work Time Among US Workers With Depression
Stewart, W. F. (2003) · JAMA · doi:10.1001/jama.289.23.3135 · Cited by 1,421 · cited 2×
“The number of workdays missed due to presenteeism associated with reduced productivity while at work was based on prior literature estimates [21].”
BackgroundMethodThe Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Simes, M., Berman, R., Koenigsberg, S. H., & Kessler, R. C. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01019-4 · Cited by 838
Self-citationGrenard, J. L., Munjas, B. A., Adams, J. L., Suttorp, M., Maglione, M., McGlynn, E. A., & Gellad, W. F. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1704-y · Cited by 635
Lakdawalla, D. N., Doshi, J. A., Garrison, L. P., Phelps, C. E., Basu, A., & Danzon, P. M. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.007 · Cited by 540
Research works printed but not linked: 2
- Voller C, Hickey C, Tan R, et al. Assessing the onset of efficacy and tolerability of pharmacological treatments in major depressive disorder: a systematic literature review and descriptive analysis. [unpublished manuscript]. 2023.
- Chitnis A, O’Callaghan L, Fournier AA, et al. Impact of living with an adult with major depressive disorder among households in the United States. J Affect Disord. 2023. (in press).
Cited by
Management of Depression in Adults: A Review
Simon, G. E., Moise, N., & Mohr, D. C. (2024) · JAMA · doi:10.1001/jama.2024.5756 · Cited by 234
Chen, X.-D., Li, F., Zuo, H., & Zhu, F. (2025) · Depression and Anxiety · doi:10.1155/da/5553491 · Cited by 97
Wu, Y., Song, J., Zhang, Q., Yan, S., Sun, X., Mei, L., Yi, W., Pan, R., Li, Y., Jin, X., et al. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.120445 · Cited by 72
Stolfi, F., Abreu, H., Sinella, R., Nembrini, S., Centonze, S., Landra, V., Brasso, C., Cappellano, G., Rocca, P., & Chiocchetti, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1422939 · Cited by 62
Exploring depression in adults over a decade: a review of longitudinal studies
de Sousa, R. D., Zagalo, D. M., Costa, T., de Almeida, J. M. C., Canhão, H., & Rodrigues, A. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06828-x · Cited by 44
“Depression leads to reduced workforce productivity, increased healthcare expenditures, and significant disability-related costs, further amplifying its societal toll [5, 5–10].”
Metadata
- Authors
- Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S.-Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A.-A., & Kessler, R. C.
- Affiliations
- Analysis Group (United States) (US)
- Biogen (United States) (US)
- Sage Therapeutics (United States) (US)
- Harvard University (US)
- Corresponding author
- Maitland, Jessica
- Venue
- Advances in Therapy
- Published
- 2023-07-31
- Volume
- 40
- Issue
- 10
- Pages
- 4460-4479
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC10499687
- OpenAlex
- W4385396235
- Cited by
- 223
- References
- 30
- Citations by year
- 2026: 90 · 2025: 89 · 2024: 35 · 2023: 3
- FWCI
- 64.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Biogen
- Sage Therapeutics
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- major depressive disorder, economic burden, social costs, health care costs, indirect costs, presenteeism, absenteeism, household costs, rapid-acting antidepressants, cost-effectiveness, prevalence, United States
- MeSH terms
- Financial Stress, Adult, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Male, United States, Prevalence, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Economic Burden of Adults with Major Depressive Disorder in the United States (2019). https://app.cochat.ai/papers/10.1007/s12325-023-02622-x
- The paper
- Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S.-Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A.-A., & Kessler, R. C. (2023). The Economic Burden of Adults with Major Depressive Disorder in the United States (2019). Advances in Therapy. https://doi.org/10.1007/s12325-023-02622-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.